Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Regeneron Pharmaceuticals
Scientific Title
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies